Teva Pharmaceutical Industries stock settles US states' case
Published on 11/17/2026 at 16:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSSettlement changes Teva's legal picture
- Teva settled litigation brought by most US states over alleged price fixing involving dozens of generic drugs.
- The case had remained active for years and involved Teva alongside numerous other defendants.
Teva Pharmaceutical Industries has settled long-running litigation brought by most US states over allegations that the drugmaker and dozens of other defendants conspired to fix prices for numerous generic medicines, Reuters reported on November 16.
Legal exposure moves toward resolution
The settlement addresses claims brought by most US states in a case that had remained active for years. Reuters said the allegations concerned price fixing across dozens of generic drugs and included numerous defendants.
For Teva, the agreement marks a significant legal development in its generics business. The report did not provide settlement terms or an amount, so the immediate financial impact cannot be quantified from the announcement.
Teva Pharmaceutical Industries
- Company: Teva Pharmaceutical Industries Ltd.
- ISIN: US8816242098
- Ticker: TEVA
Broader Israeli market coverage is available through TA-35 market reports.
More news and analyses on Teva Pharmaceutical Industries stock
